Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Lisavanbulin and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma

Trial Status: administratively complete

This phase I trial studies the side effects and best dose of lisavanbulin when given together with radiation therapy in treating patients with newly diagnosed glioblastoma. Chemotherapy drugs, such as lisavanbulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving lisavanbulin and radiation therapy may work better in treating patients with glioblastoma.